Northera Approval History

  • FDA approved: Yes (First approved February 18th, 2014)
  • Brand name: Northera
  • Generic name: droxidopa
  • Company: Chelsea Therapeutics International, Ltd.
  • Treatment for: Hypotension

Northera (droxidopa) is an orally active synthetic precursor of norepinephrine indicated for the treatment of neurogenic orthostatic hypotension.

FDA Approval History for Northera

DateArticle
Feb 18, 2014Approval FDA Approves Northera to treat Neurogenic Orthostatic Hypotension
Feb 14, 2014Chelsea Therapeutics Issues Statement Regarding Postponement of Northera NDA PDUFA Date
Jan 14, 2014FDA Advisory Panel Recommends Approval of Chelsea Therapeutics' Northera (Droxidopa) for the Treatment of Symptomatic nOH
Oct  9, 2013Chelsea Therapeutics Announces FDA Advisory Committee to Review Northera
Sep  4, 2013Chelsea Therapeutics Announces FDA Acceptance of Northera (droxidopa) NDA Resubmission
Aug 15, 2013Chelsea Therapeutics Announces Submission of Additional Information for Northera NDA
Jul 17, 2013Chelsea Therapeutics Announces FDA Acceptance of Northera (droxidopa) NDA Resubmission
Jul  9, 2013Chelsea Therapeutics Resubmits New Drug Application for Northera (droxidopa) for the Treatment of Symptomatic NOH
Feb 20, 2013Chelsea Therapeutics Receives FDA Guidance for a Northera (Droxidopa) NDA Resubmission With Study 306B
Jul  3, 2012Chelsea Therapeutics Provides an Update on Northera (droxidopa) Regulatory Status and Development Program
May 22, 2012Chelsea Therapeutics Completes End-of-Review Meeting With FDA for Northera (droxidopa) NDA
Mar 28, 2012Chelsea Therapeutics Receives Complete Response Letter from Food and Drug Administration for Northera (droxidopa) Capsules
Feb 24, 2012FDA Advisory Panel Recommends Approval of Chelsea's Northera (droxidopa) for the Treatment of Symptomatic Neurogenic OH
Feb 14, 2012Chelsea Therapeutics CEO to Review Northera NDA and Provide an Update on Upcoming Advisory Committee Meeting During Presentation at BIO CEO
Jan  5, 2012Chelsea Therapeutics Announces FDA Advisory Committee Meeting Date for Review of Northera NDA for the Treatment of Symptomatic NOH
Sep 28, 2011Chelsea Therapeutics Submits New Drug Application for Northera (droxidopa) for the Treatment of Symptomatic NOH
Dec 20, 2010Chelsea Therapeutics Accelerates Northera NDA Filing Following Meeting With FDA
Feb  9, 2010Chelsea Therapeutics Announces Advancements in Neurogenic Orthostatic Hypotension Registration Program

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)